ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

In Brief: Ovarian Cancer Coalition Opens Office; Winchester Leads Surgical Oncologists

July 11, 1997

Tracors’ Prime Contract Includes $1 Million for Additional Tests

May 17, 1974

FDA Approves Bexxar For Treatment Of Non-Hodgkin’s Lymphoma.

July 4, 2003

NIH On R29 Phase-Out; Grant Review Appeals Process Changed

January 23, 1998

Lombardi Recruits Adams-Campbell.

October 3, 2008

Oncology Groups Oppose Proposed Cuts In Medicare Payments For Cancer Drugs

October 11, 2002